Is the 4C Score Still a Valid Item to Predict In-Hospital Mortality in People with SARS-CoV-2 Infections in the Omicron Variant Era?

4C score COVID-19 Omicron variant SARS-CoV-2 antiviral treatment mortality predictive score vaccine

Journal

Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444

Informations de publication

Date de publication:
08 Jan 2023
Historique:
received: 30 11 2022
revised: 03 01 2023
accepted: 05 01 2023
entrez: 21 1 2023
pubmed: 22 1 2023
medline: 22 1 2023
Statut: epublish

Résumé

Since the start of the SARS-CoV-2 pandemic, several scores have been proposed to identify infected individuals at a higher risk of progression and death. The most famous is the 4C score. However, it was developed in early 2020. Our study aimed to evaluate the accuracy of the 4C score during the wave in which the Omicron variant was prevalent. An observational study was conducted at an Italian University Hospital between 1 January and 31 July 2022. A receiver operating characteristic (ROC) curve analysis was performed to evaluate the ability of the 4C score to predict mortality. Overall, 1186 people were recruited, of which 160 (13.5%) died. According to the 4C score, 177 (11.6%) were classified as having a low risk of mortality, 302 (25.5%) were intermediate, 596 (50.3%) were high, and 151 (12.7%) were very high. The ROC curve of the 4C score showed an AUC (95% CI) value of 0.78 (0.74−0.82). At the criterion value of > 10, the sensitivity was 76.2% and the specificity was 62.67%. Similar to previous studies, the 4C mortality score performed well in our sample, and it is still a useful tool for clinicians to identify patients with a high risk of progression. However, clinicians must be aware that the mortality rate reported in the original studies was higher than that observed in our study.

Identifiants

pubmed: 36676132
pii: life13010183
doi: 10.3390/life13010183
pmc: PMC9863404
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Vaccines (Basel). 2022 Oct 17;10(10):
pubmed: 36298596
Curr Med Res Opin. 2022 Dec;38(12):2029-2033
pubmed: 36170020
Lancet. 2022 Feb 12;399(10325):665-676
pubmed: 35151397
Inflamm Res. 2020 Dec;69(12):1181-1189
pubmed: 32918567
Panminerva Med. 2022 May 27;:
pubmed: 35622392
Lancet Respir Med. 2022 Oct;10(10):972-984
pubmed: 35817072
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
PLoS One. 2020 Nov 11;15(11):e0241825
pubmed: 33175863
N Engl J Med. 2022 Apr 14;386(15):1397-1408
pubmed: 35172054
Ann Intern Med. 2021 Jan;174(1):33-41
pubmed: 32960645
J Med Virol. 2022 Nov;94(11):5582-5588
pubmed: 35855627
Sci Rep. 2021 Sep 20;11(1):18638
pubmed: 34545103
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
Drugs Context. 2021 Jan 29;10:
pubmed: 33569082
Nat Struct Mol Biol. 2021 Sep;28(9):706-708
pubmed: 34518697
Laryngoscope. 2022 Feb;132(2):419-421
pubmed: 34812498
JAMA. 2022 Apr 5;327(13):1236-1246
pubmed: 35285853
Clin Infect Dis. 2023 Jan 6;76(1):165-171
pubmed: 35245942
Viruses. 2022 Dec 27;15(1):
pubmed: 36680111
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
J Med Virol. 2021 Jan;93(1):32-34
pubmed: 32410234
PLoS One. 2021 Jan 22;16(1):e0245840
pubmed: 33481930
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Lancet Infect Dis. 2022 Sep;22(9):1293-1302
pubmed: 35753318
Z Gesundh Wiss. 2022;30(8):1985-1993
pubmed: 35004128
PLoS One. 2021 Mar 16;16(3):e0248009
pubmed: 33724987
Lancet. 2022 Oct 8;400(10359):1213-1222
pubmed: 36216007
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
N Engl J Med. 2022 Aug 4;387(5):468-470
pubmed: 35857646
J Biomed Sci. 2022 Oct 15;29(1):82
pubmed: 36243868
J Med Virol. 2021 Feb;93(2):820-830
pubmed: 32691881

Auteurs

Andrea De Vito (A)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Agnese Colpani (A)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Laura Saderi (L)

Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Mariangela Puci (M)

Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Beatrice Zauli (B)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Maria Chiara Meloni (MC)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Marco Fois (M)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Alessandra Bitti (A)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Cosimo Di Castri (C)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Vito Fiore (V)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Ivana Maida (I)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Sergio Babudieri (S)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Giovanni Sotgiu (G)

Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Giordano Madeddu (G)

Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.

Classifications MeSH